Pediatric patients receiving a combination of rituximab and cyclophosphamide therapy for rheumatic disease showed clinical improvement with a low risk for adverse effects. While current clinical ...
Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients From the Nebraska Lymphoma Study Group PURPOSE: Rituximab was recently approved for use in relapsed, low-grade ...
In a trial, rituximab demonstrated clinical efficacy in reducing proteinuria in patients with FRNS or SDNS. Intravenous rituximab is safe and effective in patients with frequently relapsing nephrotic ...
Rituximab vs placebo significantly improved the 49-week relapse-free rate in adults with frequently relapsing or steroid-dependent adult-onset nephrotic syndrome. Adverse events were more common in ...
Epkinly, combined with Revlimid and Rituxan, shows improved progression-free survival and response rates in relapsed or refractory follicular lymphoma. The EPCORE FL-1 trial demonstrated a 79% ...
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results